CN101152189A - 多烯磷脂酰胆碱注射液及其制备方法 - Google Patents
多烯磷脂酰胆碱注射液及其制备方法 Download PDFInfo
- Publication number
- CN101152189A CN101152189A CNA2007100502239A CN200710050223A CN101152189A CN 101152189 A CN101152189 A CN 101152189A CN A2007100502239 A CNA2007100502239 A CN A2007100502239A CN 200710050223 A CN200710050223 A CN 200710050223A CN 101152189 A CN101152189 A CN 101152189A
- Authority
- CN
- China
- Prior art keywords
- polyene phosphatidylcholine
- injection
- vitamin
- benzyl alcohol
- sodium hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title claims abstract description 42
- 150000004291 polyenes Chemical class 0.000 title claims abstract description 42
- 238000002347 injection Methods 0.000 title claims abstract description 26
- 239000007924 injection Substances 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 26
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- QSHVAZMOLNGWSY-UHFFFAOYSA-N 3-butyl-4-methoxyphenol Chemical group CCCCC1=CC(O)=CC=C1OC QSHVAZMOLNGWSY-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 13
- 229940046009 vitamin E Drugs 0.000 claims abstract description 13
- 239000011709 vitamin E Substances 0.000 claims abstract description 13
- 108010007979 Glycocholic Acid Proteins 0.000 claims abstract description 12
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims abstract description 12
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims abstract description 12
- 229940099347 glycocholic acid Drugs 0.000 claims abstract description 12
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004380 Cholic acid Substances 0.000 claims abstract description 10
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 10
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 10
- 229960002471 cholic acid Drugs 0.000 claims abstract description 10
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 9
- 235000011187 glycerol Nutrition 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 46
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 10
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 239000003708 ampul Substances 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 17
- 239000000047 product Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
检测项目 | 脱炭前 | 脱炭后 | 灭菌后 |
性状 | 黄色澄明液体 | 黄色澄明液体 | 黄色澄明液体 |
PH值 | 8.95 | 8.91 | 8.79 |
含量测定PC(%) | 101.56 | 101.18 | 100.72 |
有关物质LPC(%) | 0.35 | 0.38 | 0.82 |
苯甲醇(%) | 100.37 | 100.35 | 100.19 |
项目 | 时间 | 性状 | 澄明度 | PH值 | 含量 | 有关物质(%) | |
PC(%) | 苯甲醇(%) | ||||||
0天 | 黄色澄明液体 | 符合规定 | 8.65 | 100.72 | 100.37 | 0.82 | |
高温(40℃) | 5天 | 黄色澄明液体 | 符合规定 | 8.61 | 100.63 | 100.08 | 1.06 |
10天 | 黄色澄明液体 | 符合规定 | 8.62 | 100.62 | 99.75 | 1.25 | |
光照(4500Lx) | 5天 | 黄色澄明液体 | 符合规定 | 8.67 | 100.75 | 100.40 | 0.80 |
10天 | 黄色澄明液体 | 符合规定 | 8.66 | 100.68 | 100.31 | 0.83 |
产品批次 | 检验时间 | 性状 | 澄明度 | PH值 | 含量 | 有关物质(%) | |
PC(%) | 苯甲醇(%) | ||||||
051205 | 2007.4.24 | 黄色澄明液体 | 符合规定 | 8.48 | 98.42 | 100.05 | 1.13 |
060102 | 2007.4.24 | 黄色澄明液体 | 符合规定 | 8.39 | 97.58 | 101.26 | 0.96 |
060801 | 2007.4.24 | 黄色澄明液体 | 符合规定 | 8.52 | 100.15 | 98.85 | 1.28 |
061103 | 2007.4.24 | 黄色澄明液体 | 符合规定 | 8.50 | 99.78 | 101.42 | 0.90 |
070201 | 2007.4.24 | 黄色澄明液体 | 符合规定 | 8.56 | 98.86 | 100.67 | 0.73 |
检测时间 | 0小时 | 2小时 | 4小时 | 6小时 | 8小时 | 24小时 |
性状 | 黄色澄明液体 | 黄色澄明液体 | 黄色澄明液体 | 黄色澄明液体 | 黄色澄明液体 | 黄色澄明液体 |
pH值 | 7.83 | 7.83 | 7.84 | 7.83 | 7.82 | 7.80 |
含量 | 99.51% | 99.38% | 99.45% | 99.28% | 99.25% | 98.68% |
有关物质 | 0.93% | 1.02% | 1.15% | 1.37% | 1.43% | 1.89% |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100502239A CN101152189B (zh) | 2007-10-12 | 2007-10-12 | 多烯磷脂酰胆碱注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100502239A CN101152189B (zh) | 2007-10-12 | 2007-10-12 | 多烯磷脂酰胆碱注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101152189A true CN101152189A (zh) | 2008-04-02 |
CN101152189B CN101152189B (zh) | 2010-11-24 |
Family
ID=39254209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100502239A Active CN101152189B (zh) | 2007-10-12 | 2007-10-12 | 多烯磷脂酰胆碱注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101152189B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102631313A (zh) * | 2011-11-10 | 2012-08-15 | 上海天氏利医药科技有限公司 | 一种多烯磷脂酰胆碱静脉给药制剂及其制备方法 |
CN104208136A (zh) * | 2014-09-25 | 2014-12-17 | 宁夏智弘生物科技有限公司 | 苦豆子碱奶牛乳房注入剂的制备工艺和使用方法 |
CN105997854A (zh) * | 2016-06-14 | 2016-10-12 | 成都天台山制药有限公司 | 多烯磷脂酰胆碱注射液组合物和制法 |
CN108567737A (zh) * | 2017-03-10 | 2018-09-25 | 深圳君圣泰生物技术有限公司 | 液体组合物及其使用装置 |
CN108593785A (zh) * | 2018-03-22 | 2018-09-28 | 佛山市中医院 | 一种改善伤科黄水澄明度的制备方法 |
CN108653204A (zh) * | 2018-08-01 | 2018-10-16 | 辽宁海思科制药有限公司 | 一种多烯磷脂酰胆碱注射液药物组合物及其制备方法 |
WO2018194427A1 (ko) * | 2017-04-21 | 2018-10-25 | 이기택 | 통증과 부종 그리고 부작용이 없는 국소지방 감소용 주사제 조성물 및 이의 제조방법 |
WO2019156453A1 (ko) * | 2018-02-07 | 2019-08-15 | 이기택 | 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물 |
-
2007
- 2007-10-12 CN CN2007100502239A patent/CN101152189B/zh active Active
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102631313A (zh) * | 2011-11-10 | 2012-08-15 | 上海天氏利医药科技有限公司 | 一种多烯磷脂酰胆碱静脉给药制剂及其制备方法 |
CN104208136A (zh) * | 2014-09-25 | 2014-12-17 | 宁夏智弘生物科技有限公司 | 苦豆子碱奶牛乳房注入剂的制备工艺和使用方法 |
CN105997854B (zh) * | 2016-06-14 | 2018-11-27 | 成都天台山制药有限公司 | 多烯磷脂酰胆碱注射液组合物和制法 |
CN105997854A (zh) * | 2016-06-14 | 2016-10-12 | 成都天台山制药有限公司 | 多烯磷脂酰胆碱注射液组合物和制法 |
CN108567737A (zh) * | 2017-03-10 | 2018-09-25 | 深圳君圣泰生物技术有限公司 | 液体组合物及其使用装置 |
JP7034497B2 (ja) | 2017-04-21 | 2022-03-14 | アミ ファーム カンパニー リミテッド | 痛み、浮腫及び副作用のない局所脂肪減少用注射剤組成物及びその製造方法 |
WO2018194427A1 (ko) * | 2017-04-21 | 2018-10-25 | 이기택 | 통증과 부종 그리고 부작용이 없는 국소지방 감소용 주사제 조성물 및 이의 제조방법 |
CN109862897A (zh) * | 2017-04-21 | 2019-06-07 | 啊美药业 | 无痛、无水肿且无副作用的局部减脂可注射组合物及制备其的方法 |
JP2020517581A (ja) * | 2017-04-21 | 2020-06-18 | アミ ファーム カンパニー リミテッド | 痛み、浮腫及び副作用のない局所脂肪減少用注射剤組成物及びその製造方法 |
RU2736974C1 (ru) * | 2017-04-21 | 2020-11-23 | Ами Фарм Ко., Лтд. | Инъецируемая композиция для уменьшения локализованного жира без болевого синдрома, отёка и побочных эффектов и способ ее получения |
US11298314B2 (en) | 2017-04-21 | 2022-04-12 | Ami Pharm Co., Ltd. | Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same |
IL266873B1 (en) * | 2017-04-21 | 2023-12-01 | Ami Pharm Co Ltd | An injectable preparation for local fat reduction without pain, edema and side effects, and a method for its preparation |
CN109862897B (zh) * | 2017-04-21 | 2024-01-30 | 啊美药业 | 无痛、无水肿且无副作用的局部减脂可注射组合物及制备其的方法 |
IL266873B2 (en) * | 2017-04-21 | 2024-04-01 | Ami Pharm Co Ltd | An injectable preparation for local fat reduction without pain, edema and side effects, and a method for its preparation |
WO2019156453A1 (ko) * | 2018-02-07 | 2019-08-15 | 이기택 | 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물 |
CN108593785A (zh) * | 2018-03-22 | 2018-09-28 | 佛山市中医院 | 一种改善伤科黄水澄明度的制备方法 |
CN108653204A (zh) * | 2018-08-01 | 2018-10-16 | 辽宁海思科制药有限公司 | 一种多烯磷脂酰胆碱注射液药物组合物及其制备方法 |
CN108653204B (zh) * | 2018-08-01 | 2022-04-08 | 海思科制药(眉山)有限公司 | 一种多烯磷脂酰胆碱注射液药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101152189B (zh) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101152189B (zh) | 多烯磷脂酰胆碱注射液及其制备方法 | |
CN102470176B (zh) | 药物制剂 | |
JPH0510327B2 (zh) | ||
CN104382941A (zh) | 一种人工熊胆粉及其制备方法 | |
CN1283235C (zh) | 清澈稳定的丙泊酚组合物 | |
CN102225048A (zh) | 一种姜黄素类化合物注射溶液及其静脉注射剂 | |
CN101455631A (zh) | 环磷腺苷葡胺注射液及其制备工艺 | |
CN101045042B (zh) | 丙泊酚注射液及制备方法 | |
CN102525918A (zh) | 一种丁酸氯维地平的脂肪乳注射液及其制备工艺 | |
CN104546706B (zh) | 一种右旋布洛芬注射乳剂及其制备方法 | |
CN104080460A (zh) | 不含脱氧胆酸钠的含磷脂酰胆碱的可注射组合物及其制备方法 | |
CN104288210A (zh) | 一种长链脂肪乳注射用药物组合物及其制备方法 | |
CN107789317A (zh) | 一种硫辛酸注射液及制备方法 | |
CN105997854B (zh) | 多烯磷脂酰胆碱注射液组合物和制法 | |
CN102144963A (zh) | 胞磷胆碱钠葡萄糖注射液及其制备工艺 | |
CN101417105A (zh) | 一种莪术油葡萄糖注射液及其制备方法 | |
CN101756895A (zh) | 一种多烯磷脂酰胆碱静脉制剂及其制备方法 | |
CN101244070A (zh) | 一种多烯磷脂酰胆碱大容量注射液 | |
CN109152785B (zh) | 医药组合物 | |
CN101543520A (zh) | 艾叶油液体胶囊及其制备方法 | |
CN103239392B (zh) | 一种奥硝唑注射制剂及制备方法 | |
JP2005143317A (ja) | 植物ステロールを含有する水分散型製剤 | |
CN108158989B (zh) | 一种盐酸氨溴索注射液组合物 | |
EP3490578A1 (en) | Curcumin-based pharmaceutical compositions and methods for fabricating thereof | |
CN113197847A (zh) | 一种含有去乙酰毛花苷的药物组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: XIZHANG KANGXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENGDU HANLANG BIOTECHNOLOGY CO., LTD. Effective date: 20090515 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090515 Address after: Tibet Shannan Zedang town Xiang Qu Road No. 8 post encoding: 856000 Applicant after: Tibet Kangxin Pharmaceutical Co., Ltd. Address before: B-C-36, building No.1, high tech incubator Park, South Tianfu Road, Tianfu Road, Sichuan, Chengdu Province, China: 610041 Applicant before: Chengdu Hanming Biotechnology Co.Ltd |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: The 856000 Tibet autonomous region in southern area of Zedang town Xiang Qu Road No. 8 Patentee after: Tibet Haisco Pharmaceutical Group Co., Ltd. Address before: The 856000 Tibet autonomous region in southern area of Zedang town Xiang Qu Road No. 8 Patentee before: Tibetan Haisike Pharmaceutical Group Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SICHUAN HAISCO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TIBET HAISCO PHARMACEUTICAL GROUP CO., LTD. Effective date: 20110816 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 856000 LHOKA PREFECTURE, TIBET AUTONOMOUS REGION TO: 611130 CHENGDU, SICHUAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110816 Address after: The two sides of the Chengdu Straits Technology Industry Development Park Baili road Wenjiang District 611130 Sichuan city of Chengdu Province, No. 136 Patentee after: Sichuan Haisco Pharmaceutical Co.,Ltd. Address before: The 856000 Tibet autonomous region in southern area of Zedang town Xiang Qu Road No. 8 Patentee before: Tibet Haisco Pharmaceutical Group Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20080402 Assignee: Chengdu Tiantaishan Pharmaceutical Co., Ltd. Assignor: Sichuan Haisco Pharmaceutical Co.,Ltd. Contract record no.: 2016510000025 Denomination of invention: Polyene phosphatidyl choline injection and method for preparing the same Granted publication date: 20101124 License type: Common License Record date: 20161111 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170811 Address after: The two sides of the Chengdu Straits Technology Industry Development Park Baili road Wenjiang District 611130 Sichuan city of Chengdu Province, No. 136 Co-patentee after: Haisike Pharmaceutical Group Limited by Share Ltd Patentee after: Sichuan Haisco Pharmaceutical Co.,Ltd. Address before: The two sides of the Chengdu Straits Technology Industry Development Park Baili road Wenjiang District 611130 Sichuan city of Chengdu Province, No. 136 Patentee before: Sichuan Haisco Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
EM01 | Change of recordation of patent licensing contract |
Change date: 20180629 Contract record no.: 2016510000025 License type after: Exclusive license License type before: General permission Change date: 20180629 Contract record no.: 2016510000025 Assignor after: Sichuan Hai CISCO Pharmaceutical Co., Ltd. Assignor after: Hai Cisco Pharmaceutical Group Co., Ltd. Assignor before: Sichuan Haisco Pharmaceutical Co.,Ltd. |
|
EM01 | Change of recordation of patent licensing contract |